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Abstract: Choroidal neovascularization (CNV) is a key pathological feature of several leading
causes of vision loss including neovascular age-related macular degeneration. Here, we show that
a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic
activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat
aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection
of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein
angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 µg and 20 µg of CAD27
injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received
topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 µg/mL and
20 µg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using
electroretinography in both groups receiving interareal injection or topical applications of CAD27
for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic
alternative for targeting CNV in diseases such as neovascular age-related macular degeneration.
Keywords: choroidal neovascularization; neovascular age-related macular degeneration; calreticulin
anti-angiogenic domain
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1. Introduction
Choroidal neovascularization (CNV) is the primary cause of vision loss in patients with wet
(exudative or neovascular) age-related macular degeneration (nAMD) and degenerative myopia [1,2].
In these conditions, abnormally high levels of vascular endothelial growth factor (VEGF) are secreted.
Elevated levels of VEGF cause the pathological formation of blood vessels in the eye, which can
lead to vision loss due to the leakage of blood and fluid into the retina. The recent availability of
anti-VEGF therapies (VEGF-neutralizing proteins, such as monoclonal antibodies, antibody fragments,
and antibody-receptor fusion proteins) has revolutionized the treatment for CNV by preserving,
and even restoring, vision for patients [3,4]. However, existing anti-VEGF therapeutics are expensive
and require frequent intravitreal injections (often for many years) to achieve a therapeutic benefit.
Moreover, a limited capacity for repeated injections in the public health system poses a barrier to
access for patients. Thus, there is an urgency to seek cost-effective, less invasive, and more durable
alternative therapies for these conditions.
The calreticulin anti-angiogenic domain (CAD; also known as vasostatin) is the N-terminal domain
of calreticulin, comprising amino acids 1–180. It is a potent endogenous inhibitor of angiogenesis [5].
Recombinant CAD has previously inhibited basic fibroblast growth factor (bFGF)- or the VEGF-induced
angiogenic response of human endothelial cells [6–8] by preventing endothelial cell attachment to
laminin, which attenuates the angiogenic response of endothelial cells [9]. CAD has anti-inflammatory
properties, which potentiates its anti-angiogenic effects by limiting inflammation-driven angiogenic
triggers [10]. Moreover, intramuscular gene delivery or topical application of CAD has been
demonstrated to suppress corneal and choroidal neovascularization in rats. Here, we have expanded
upon the scope of previous studies by focusing on the functional domain of CAD, which was a cyclic
peptide fragment of 27 residues comprising residues 137–163 of calreticulin, referred to as CAD-like
peptide 27 (CAD27). Next, we investigated the anti-angiogenic effect and therapeutic efficacy of
CAD27 in vitro and in vivo in a rat model of laser-induced CNV via intravitreal administration and
topical application.
2. Results
2.1. Identify the Functional Domain of CAD for the Inhibition of Angiogenesis
To identify the functional fragment of CAD, a stop codon was introduced into the different
amino acid sequences of the thioredoxin (TrxA)-CAD48 construct by site-directed mutagenesis to
generate truncated CAD proteins (T141, N149, I157, D165, and T173) (Figure 1A,B). The recombinant
proteins were overexpressed as TrxA-tagged proteins in Escherichia coli and purified using Ni-NTA
affinity chromatography. The purity of the purified proteins was estimated to be approximately
90% (Figure 1C). Subsequently, we performed a Boyden’s chamber migration assay to examine the
effects of the truncated CAD fragments on the angiogenic activity of primary human endothelial
cells (HUVECs). As shown in Figure 1D, the migration of HUVECs was significantly reduced by the
treatment of TrxA-I157, TrxA-D165, and TrxA-T173 protein (TrxA-I157: 44 ± 13, n = 3; TrxA-D165:
33 ± 10, n = 3; TrxA-T173: 25 ± 7, n = 3), whereas the migration of HUVECs was not affected by TrxA,
TrxA-T141, and TrxA-T149 protein (the number of migrated cells in TrxA: 87 ± 7, n = 3; TrxA-T141:
99± 14, n = 3; TrxA-T149: 70± 9, n = 3). These results suggest that the CAD fragments covering 149–165
amino acid residues were responsible for the inhibition of endothelial cell migration. In addition,
we further generated two truncated CAD fragments, CAD27 and CAD36, which consisted of residues
C137–C162 and C137–Y172 of CAD encompassing the functional motif of the anti-angiogenic domain
in a cyclic structure format (Figure 1A,B). Our data showed that TrxA-CAD27 (24 ± 3, n = 3) and
TrxA-CAD36 (residues C137-Y172; 38 ± 5, n = 3) have comparable function in inhibiting the migration
of HUVECs to TrxA-CAD48 (18 ± 2, n = 3) (Figure 1D).
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Figure 1. The effect of truncated CAD on the inhibition of angiogenesis. (A) Schematic diagram of 
CAD and its truncated protein constructs. Five truncated CAD fragments derived from CAD48 were 
generated by introducing a stop codon on each amino acid sequence of T141, N149, I157, D165, and 
T173. CAD36 (residues C137–Y172) and CAD27 (residues C137–C163) were further generated 
according to the functional motif of CAD48 and can form in a cyclic structure. N: N-terminal domain. 
C: C-terminal domain. SP: Signal peptide. NF: Nonfunctional domain. AD: anti-angiogenic domain. 
(B) Amino acid sequence of TrxA-CAD recombinant proteins. The yellow square box indicates 
truncated CAD fragments. * Stop codon. (C) Purification and SDS-PAGE analysis of the recombinant 
fragments of truncated CAD. (D) Effects of the CAD48 and its truncated fragments (green and yellow 
bars) on migration of primary human endothelial cells (HUVECs). The quantification of migration 
assay characterizing migrated cells and data are presented as the mean ± SEM (n = 3). Statistical 
analysis between groups was performed using one-way ANOVA followed by Tukey’s multiple 
comparisons test (* p < 0.05, ** p < 0.001, *** p < 0.0001). 
Figure 1. The effect of truncated CAD on the inhibition of angiogenesis. (A) Schematic diagram of
CAD and its truncated protein constructs. Five truncated CAD fragments derived from CAD48 were
generated by introducing a stop codon on each amino acid sequence of T141, N149, I157, D165, and T173.
CAD36 (residues C137–Y172) and CAD27 (residues C137–C163) were further generated according to
the functional motif of CAD48 and can form in a cyclic structure. N: N-terminal domain. C: C-terminal
domain. SP: Signal peptide. NF: Nonfunctional domain. AD: anti-angiogenic domain. (B) Amino
acid sequence of TrxA-CAD recombinant proteins. The yellow square box indicates truncated CAD
fragments. * Stop codon. (C) Purification and SDS-PAGE analysis of the recombinant fragments
of truncated CAD. (D) Effects of the CAD48 and its truncated fragments (green and yellow bars)
o migration of pri ary human en thelial cells (HUVECs). The quantific tion of migrati n assay
characterizing migrated cells and data are presented as the mean ± SEM (n = 3). Statistical analysis
between groups was erformed sing o e-way ANOVA followed by Tukey’s multiple c mparisons
test (* p < 0.05, ** p < 0.001, *** p < 0.0001).
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2.2. CAD27 Inhibits the Angiogenic Activity of Endothelial Cells In Vitro and Vascular Sprouting from Rat
Aortic Ring Ex Vivo
The CAD27 cyclic peptide was manufactured by de novo synthesis for in vitro and in vivo studies
(Figure 2A). To evaluate the anti-angiogenic effect of CAD27 peptides, endothelial tube formation,
migration, and rat aortic ring assays were performed. Compared with the vehicle (the percentage
of lumen count: 100 ± 1.5%, n = 4) or Csr27-treated cells (Csr27 10 µg/mL: 92.6 ± 2.5%, n = 4; and
Csr27 20 µg/mL: 99.6 ± 1.3%, n = 4), cells treated with CAD27 (CAD27 10 µg/mL: 17.4 ± 2.3%, n = 4;
and CAD27 20 µg/mL: 1.7 ± 0.8%, n = 4) showed a significant decrease in their capacity to form
tube-like networks on the Matrigel (Figure 2B). Additionally, CAD27-treated cells also showed a poorer
migration in the Boyden’s chamber migration assay (the number of migrated cells in vehicle: 134 ± 9,
n = 4; Csr27 10 µg/mL: 116 ± 8, n = 3; or Csr27 20 µg/mL: 123 ± 2, n = 3; compared with CAD27
10 µg/mL: 77 ± 6, n = 3; or CAD27 20 µg/mL: 67 ± 5, n = 3) (Figure 2C).
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Figure 2. The effect of CAD27 on in vitro angiogenic activities. (A) Schematic representation of CAD27.
CAD27 was derived from anti-angiogenic domain (residues 137–163) of calreticulin. N: N-terminal
domain. C: C-terminal domain. SP: Signal peptide. NF: Nonfunctional domain. AD: anti-angiogenic
domain. (B,C) Effect of CAD27 on tube formation and migration in human endotheli l cells
(EA.hy926) was assessed. (B) Representative images and quantitative a alysis of tube f rmation
assay characterizing the lumen formation, and data are presented as the mean ± SEM (n = 4). Scale bar:
100 µm. (C) Representative images and quantification of migration assay characterizing migrated
cells, and data are presented as the mean ± SEM (n = 3–4). Scale bar: 100 µm. Statistical analysis
between groups was performed using one-way ANOVA followed by Tukey’s multiple comparisons
test (** p < 0.001).
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To further validate the anti-angiogenic function of CAD27 ex vivo, the rat aortic rings were
embedded in Matrigel to assess microvascular sprouting. A significant reduction of vessel sprouting
from aortic ring was found in the CAD27-treated group (the percentage of sprouting length:
12.2 ± 0.7%, n = 5) compared to the vehicle-(100 ± 3.4%, n = 5) or Csr27-treated group (89.7 ± 0.9%,
n = 5) (Figure 3).Int. J. Mol. Sci. 2018, 19, x 5 of 13 
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Figure 3. The effect of CAD27 on vascular sprouting from rat aortic ring explants. (A) Representative
images and (B) quantitative analysis of vascular sprouting in 3 week-old rat aortic ring explants.
Data are presented as the mean ± SEM (n = 5). Statistical analysis between groups was performed
using one-way ANOVA followed by Tukey’s multiple comparisons test (** p < 0.001). Red lines
indicated the border zone of vascular sprouting.
2.3. Effect of Intravitreal or Topical Delivery of CAD27 on Retinal Function in the Rat Retina
Electroretinography (ERG) was employed to evaluate the effects of CAD27 on retinal function in
rats 14 days after its intravitreal injection or topical applic tion. There were no statistical differences i
the l tency and amplitude of the a-w ve and b-wave in the eyes which received eith r the intr vitre l
injectio or topical application of CAD27 compared to those recei ing eith r the vehicl or Luc ntis®
(ranibizumab) (n = 12; Table 1 and Supplementary Figure S1). Thus, our results suggest that intravitreal
injection or topical application of CAD27 does not lead to detectably adverse eff cts on retinal function.
Table 1. The effect of intravitreal and topical application of CAD27 on retinal function assessed by
electroretinography (ERG).
ERG Parameters Vehicle Lucentis
®
(IVI)
CAD27
(10 µg, IVI)
CAD27
(20 µg, IVI)
CAD27
(10 µg/mL, TA)
CAD27
(20 µg/mL, TA) p Value
a-wave amplitude, µV −128.6± 11.1 −145.7± 10.9 −161.4± 14.7 −142.1± 10.2 −159.9 ± 10.3 −163.3 ± 9.2 0.1557
a-wave latency, ms 19.7 ± 0.7 20.0 ± 0.6 17.8 ± 0.9 19.8 ± 1.0 18.2 ± 0.5 18.7 ± 0.4 0.0834
b-wave amplitude µV 296.5 ± 15.2 314.3 ± 20.8 351.1 ± 27.2 310.1 ± 29.7 336.5 ± 19.9 367.1 ± 22.4 0.1522
b-wave latency, ms 58.7 ± 1.5 55.1 ± 1.4 51.9 ± 2.2 52.2 ± 2.5 54.8 ± 1.5 54.2 ± 1.3 0.0675
Statistical analysis was performed using one-way ANOVA. IVI: intravitreal injection, TA: topical application.
2.4. In ravitreal and Topical Delive y of CAD27 Alleviates Laser-Induced CNV Lesions in Rats
A rat model of laser-induced CNV was employed to evaluate the therapeutic potential of
intravitreal and topical delivery of CAD27. One day after the laser surgery, CAD27 was administered
via a single intravitreal injection or daily topical application (three times a day) in the CNV rats.
The extent of choroidal vascularization was exa ined using fundus fluorescein angiography and
choroidal flat-mounts with FITC-dextran perfusion on days 24 and 28 after CNV induction (Figure 4A),
respectively. Compared to the vehicle-treated eyes (60% of the eyes had score 3, 33% had score 2,
and 7% had score 1, n = 42), intravitreal injection of CAD27 (10 µg CAD27: 11% of the eyes had score 3,
52% had score 2, and 37% had score 1, n = 27; 20 µg CAD27: 2% of the eyes had score 3, 43% had score 2,
and 55% had score 1, n = 40) and Lucentis® (8% of the eyes had score 3, 46% had score 2, and 46% had
score 1, n = 26) reduced the CNV score, measured by FFA, on day 24 (Figure 4B,C). Similarly, the daily
topical application of CAD27 also reduced the CNV score (10 µg/mL CAD27: 2% of the eyes had
score 3, 58% had score 2, and 40% had score 1, n = 46; 20 µg/mL CAD27: 3% of the eyes had score 3,
30% had score 2, and 67% had score 1, n = 44) (Figure 4B,C).
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Figure 4. Fluorescein angiographic analysis of choroidal neovascularization (CNV) lesions after
an intravitreal or daily topical application of CAD27. (A) A schematic diagram of the timeline for the
laser-induced CNV rat model, treatments, and examination. Choroidal vascularity of laser-induced
CNV lesions was examined by FFA (day 24) and choroidal flat-mount labeling with FITC-dextran
(day 28) after a single intravitreal injection or daily topical application of CAD27. (B) Representative
CNV lesions in rat eyes were identified by fundus fluorescein angiography after an intravitreal or
daily topical application of CAD27. Yellow arrows indicated the lesions of CNV. (C) CNV lesions from
fluorescein angiography were analyzed at days 24 after treatment, and data are presented as percentage
of CNV score (n = 26–46 from 6 to 8 eyes). Score 1 (green) indicates staining, Score 2 (yellow) indicates
moderat leakage, and Score 3 (red) indicates heavy leakage. Lu: Lucentis®, IVI: intravitreal injecti n,
TA: top cal application.
To further confirm the therapeutic potential of CAD27, the size of the CNV lesion was
measured using the flat-mount analysis after perfusion with FITC-dextran on day 28 (Figure 5A
and Supplementary Figure S2). Compared to the vehicle-treated eyes (the CNV size: 82,867 ± 4880
(95% CI: 73,303–92,430) µm2, n = 30), a significant reduction in the size of CNV lesion was found in the
rat eyes that had received an intravitreal administration of CAD27 (CAD27 10 µg: 66,714 ± 2589 (95%
CI: 61,640–71,787, n = 31) µm2 and CAD27 20 µg: 64,327 ± 2341 (95% CI: 59,738–68,915, n = 23) µm2)
and Lucentis® (62,233± 3050 (95% CI: 56,256–68,209, n = 30) µm2) as well as daily topical application of
CAD27 (CAD27 10 µg/mL: 67,959 ± 2313 (95% CI: 63,425–72,492, n = 26) µm2 and CAD27 20 µg/mL:
55,911 ± 3771 (95% CI: 48,519–63,302, n = 26) µm2; Figure 5B). These results indicate that intravitreal
and topical application of CAD27 attenuated the severity of experimental CNV.
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that the de novo synthetic CAD27 cyclic peptides can inhibit angiogenesis in vitro and ex vivo and 
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Treatment for nAMD has recently been revolutionized by the availability of intravitreal anti-
VEGF agents [11]. Such agents that bind to VEGF, thereby preventing Flt-1 and KDR/Flk-1 signaling 
and inhibiting the neovascular response, have been shown to be superior to previous treatment 
modalities such as verteporfin photodynamic therapy [12]. While there is promise for improvement 
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Figure 5. Flat-mount analysis of choroidal vascularity after an intravitreal or daily topical application
of CAD27. Choroidal vascularity of laser-induced CNV lesions was examined by labeling using
FITC-dextran. (A) Representative profile of FITC-dextran-positive blood vessels in choroidal
flat-mounts at day 28 after treatment. Scale bar: 200 µm. (B) FITC-dextran labeling CNV in the
choroidal flat-mounts was quantified and data are presented as mean ± SEM (n = 26–31 from 6 to 8
eyes) using one-way ANOVA followed by Tukey’s multiple comparisons test (* p < 0.05, ** p < 0.001,
*** p < 0.0001). White area indicated the lesions of CNV in choroid flat-mount. Lu: Lucentis®,
IVI: intravitreal injection, TA: topical application.
3. Discussion
In the present study, we have identified the core anti-angiogenic domain of CAD and
demonstrated that the de novo synthetic CAD27 cyclic peptides can inhibit angiogenesis in vitro
and ex vivo and suppress ocular neovascularization in vivo. Specifically, we have confirmed the
anti-angiogenic activity of CAD27 by its inhibition of endothelial tube formation and migration, as well
as its capacity to reduce the incidence of vascular sprouting from rat aortic ring. Intravitreal and topical
application of CAD27 attenuated laser-induced CNV in rats as revealed by using FFA and choroidal
flat-mount, and no detectable adverse effects on retinal function was found by ERG.
Treatment for nAMD has recently been revolutionized by the availability of intravitreal
anti-VEGF agents [11]. Such agents that bind to VEGF, thereby preventing Flt-1 and KDR/Flk-1
signaling and inhibiting the neovascular response, have been shown to be superior to previous
treatment modalities such as verteporfin photodynamic therapy [12]. While there is promise for
improvement in vision with intravitreal anti-VEGF agents, there are also shortcomings in terms of
variable response to therapy as well as loss of efficacy in a subgroup of patients. Over the years,
many endogenous inhibitors of angiogenesis including various anti-angiogenic peptides, hormone
metabolites, and apoptosis modulators have been discovered and proposed as potential therapeutic
alternatives for targeting neovascularization and/or excessive vascular leakage in the eye [13]. Some of
them have reached clinical trial stages including Pigment epithelium-derived factor (ClinicalTrials.gov
Identifier: NCT00109499) and endostatin/angiostatin (RetinoStat) (ClinicalTrials.gov Identifier:
NCT01678872 and NCT01301443) for the treatment of nAMD. Similar to these endogenous angiogenesis
inhibitors, CAD is also a naturally occurring anti-angiogenic peptide derived from human calreticulin.
Unlike most of the angiogenesis inhibitors, which appear to have more complex activities, CAD
specifically targets proliferating endothelial cells with low toxicity [7,14,15]. Moreover, CAD appears to
have a four- to ten-fold lower effective dose then endostatin and angiostatin for angiogenesis inhibition
in vivo [16,17], as well as having anti-inflammatory properties that will help to control inflammation,
which is a major contributor to the ongoing drive for neovascularization in nAMD [10]. These favorable
features make CAD superior to previously identified angiogenesis inhibitors, which are derived from
fragments of endogenous precursor proteins, and current therapeutic approaches (e.g., anti-VEGF
antibody injections).
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Our previous studies have demonstrated that the gene delivery of CAD and its derived fragment
(CAD112) can attenuate the development of choroidal and retinal neovascularization in rodent models
of laser-induced CNV and oxygen-induced retinopathy [18]. However, adverse effects associated
with prolonged expression of vascular targeting proteins by gene delivery may have unwanted side
effects, including retinal vascular toxicity. There are also other major obstacles to the acceleration
of gene therapy from bench to bedside, such as cost of the treatment [19]. Therefore, in the present
study, we rationally designed a small fragment of CAD, CAD27, which covers the core anti-angiogenic
domain of CAD and can be produced by chemical synthesis at a lower cost than its parent molecule,
recombinant CAD protein or CAD gene therapy. Moreover, the CAD27 peptide can be cyclized by
head-to-tail to form a secondary cyclic structure, which is linked by a disulfide bond between cysteine
residues through cysteine 1–27. The cyclic engineering peptide presents several additional properties,
such as its large surface area-to-volume ratio conferring high affinity and selectivity for the target
ligand, high stability, and lower immunogenicity and low toxicity, offering a promising approach
to improve its biological activity [20,21]. Our data show that synthetic CAD27 peptide treatment
provided similar benefits in the inhibition of CNV formation compared to recombinant CAD protein
(CAD112), suggesting that the chemically synthetic peptides did not alter its anti-angiogenic properties
(Supplementary Figure S3). In addition, intravitreal and topical application of CAD27 also showed
a similar inhibitory effect on the reduction of CNV lesions compared with Lucentis® (ranibizumab),
a standard treatment option for nAMD. Thus, these data make a compelling case that CAD27 delivered
by intravitreal or topical application can be used as a therapeutic alternative to conventional therapies
for pathologic ocular neovascularization.
Intravitreal and topical routes were used to assess the therapeutic effect of CAD27 for the treatment
of CNV. Intravitreal injection has been considered an effective way to administer pharmacological
treatments to the eye for managing pathological conditions associated with abnormal blood vessel
growth, such as nAMD and diabetic retinopathy, which require life-long, frequent intravitreal injections.
Nevertheless, retinal specialists are not easily accessible in either regional communities, or less
developed or developing countries for intraocular injections, meaning that the diseases will eventually
progress to blindness. Intravitreal injection also carries risks of potentially blinding complications
and serious intraocular infections. The topical application of ophthalmic formulation is the most
convenient, safe, effective, and least invasive drug delivery method, and could potentially eliminate
the risks associated with eye injections, as well as increase accessibility for patients. Several studies
have previously demonstrated the feasibility of topical application of ophthalmic formulation for
the management of CNV [22–25]. Therefore, in the present study, we have assessed the therapeutic
potential of CAD27 for targeting CNV delivered via both intravitreal injection and topical application.
Indeed, our data indicate both delivery routes provide similar benefits in reducing CNV lesions,
suggesting that both the drug delivery methods are available and effectual in the rat laser-induced
CNV model. These data are also consistent with our previous study which showed that the topical
delivery of recombinant CAD proteins (CAD180 and 48) attenuates the development of CNV in the
laser-induced CNV model [26,27]. Moreover, CAD27 may have additional benefits over CAD180
or 48 as it can be chemically synthesized and possesses a low molecular weight which allows it to
have better retinal or transscleral penetration to the posterior segment when administered through
intravitreal injection and topical application, respectively. Further research is needed to confirm its
pharmacokinetic profile and bioavailability in the eye, particularly following topical administration.
In addition, by using in vivo ERG assessment, we showed that intravitreal or topical application of
CAD27 had little effect on retinal function over the course of 14 days. However, the long-term safety
of CAD27-based therapy will need to be confirmed before their translation into clinical trials.
In summary, our study demonstrates that the therapeutic delivery of CAD27 attenuates the
formation of CNV in vivo. Although further investigations are required to assess its pharmacokinetic
profile and long-term efficacy, our data suggest that the topical application of CAD27 may be a viable
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therapeutic alternative for CNV, as it does not require ocular injection and can thus circumvent the
risks associated with frequent injections required for current therapies.
4. Materials and Methods
4.1. Site-Directed Mutagenesis
CAD48 cDNA was amplified via polymerase chain reaction (PCR) from CAD and subcloned
into the restriction digest sites of NdeI and XhoI of the pET32a(+) vector (catalog no. 69015, Novagen
Inc., Madison, WI, USA) to yield the pET32a(+)-CAD48 plasmid (Supplementary information).
Point mutations were introduced by PCR using the QuikChange Site-Directed Mutagenesis kit (catalog
no. 200519, Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions.
The mutagenic oligonucleotide primers were designed using a web-based QuikChange Primer Design
Program (www.agilent.com/genomics/qcpd) and are shown in Supplementary Table S1. PCRs for
single amino acid mutations were run for 18 cycles of 30 s at 95 ◦C, 1 min at 55 ◦C, followed by 1 min
at 68 ◦C. The resulting mutant plasmids were verified by DNA sequencing.
4.2. Expression and Purification of Recombinant TrxA-Tagged Truncated CAD Protein
Recombinant TrxA-CAD was expressed and purified as previously described [7]. Briefly, pET32a(+)-
CAD48 or mutant plasmid was transformed in BL21(DE3)pLysS Competent Cells (catalog no. 69451,
Novagen Inc.) and the transformed cells were grown at 37 ◦C until log-phase (optical density (OD
600 nm) of 0.5 to 0.9). Expression of P protein was induced by the addition of 1 mM isopropyl
thiogalactose (IPTG; catalog no. I6758, Sigma-Aldrich, St. Louis, MO, USA) and the culture was
incubated for an additional 3 h. The cell pellet was harvested by centrifugation at 5000 rpm for
10 min at 4 ◦C, resuspended in the binding buffer (20 mM phosphate buffer, pH 7.4, 20 mM imidazole,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 µg/mL aprotinin, 1 µg/mL leupeptin, and 1 µg/mL
pepstatin), and then homogenized by sonication. After centrifugation at 12,000 rpm for 20 min at 4 ◦C,
the supernatant was mixed with Ni-NTA agarose (catalog no. 30210, Qiagen, Valencia, CA, USA) at
4 ◦C for 30 min. The beads were washed four times with the binding buffer, and the recombinant
protein was eluted with buffer (20 mM phosphate buffer, pH 7.4, 250 mM imidazole, 150 mM NaCl).
Salted and endotoxin were removed by passing through a G-25 Sephadex column (catalog no. 17085101,
GE Healthcare Life Sciences, Pittsburgh, PA, USA) and Detoxi-G gel (catalog no. 88270, Pierce, Rockford,
IL, USA).
4.3. Preparation of CAD27 Peptide
CAD27 peptide (CGPGTKKVHVIFNYKGKNVLINKDIRC) and the presumed nonfunctional form
of the scrambled peptide (Csr27; CVKIGLRGNTVKPYKFNIKDHVGKNIC) were manufactured by de
novo peptide synthesis (Kelowan Incs, Taipei, Taiwan). The synthesized peptides were reconstituted
in Dulbecco’s Phosphate Buffered Saline (DPBS; catalog no. 14190144, Gibco™, Invitrogen, Carlsbad,
CA, USA) for in vitro and in vivo studies.
4.4. Cell Culture
Human primary umbilical vein endothelial cell, HUVEC, was purchased from Lonza (catalog
no. CC-2519; Walkersville, MD, USA) and cultured in endothelial cell basal medium-2 (EBM-2)
supplemented with the EGM™-2 BulletKit™ (catalog no. CC-5035; Lonza) in a humidified 5% CO2
incubator at 37 ◦C. Human endothelial cells line, EA.hy926, was purchased from ATCC (CRL-2922™)
and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; catalog no. 11965118, Invitrogen)
supplemented with Penicillin-Streptomycin (50 U/mL; catalog no. 15140122, Invitrogen), 10% fetal
bovine serum (FBS; Gibco™, Invitrogen) and L-glutamine (2 mM; catalog no. 25030081, Invitrogen) in
a humidified 5% CO2 incubator at 37 ◦C.
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4.5. Tube Formation Assay
Quantification of tube formation was performed using a previously described method [26]. Briefly,
a 24-well plate was pre-incubated with BD Matrigel™ Basement Membrane Matrix (catalog no. 356234,
BD Biosciences, Franklin Lakes, NJ, USA) at 37 ◦C for 30 min. Cells were incubated with DPBS, CAD27
(10 and 20 µg/mL), or Csr27 (10 and 20 µg/mL) at 37 ◦C for 5 h. Cells (1.5 × 104) were resuspended in
the completed medium and loaded on the top of the Matrigel. Following 6 h incubation at 37 ◦C, each
well was photographed under a bright field phase contrast microscope. The number of endothelial
tube lumens was counted in three replicate wells and only the completed ring structures created by
three to five endothelial cells were considered as tubes. The analysis was performed in Image J version
1.48 software (http://imagej.nih.gov/ij/; provided in the National Institutes of Health, Bethesda,
MD, USA).
4.6. Cell Migration Assay
Cell migration was performed in a Boyden’s chambers (catalog no. CBA-100-C, Cell Biolabs, INC,
CA, USA), which comprises upper and lower systems separated by a 0.005% gelatin coating 8-µm
pore size polycarbonate membrane, as previously described [26]. Cells (2 × 104) were resuspended in
serum-free medium, loaded onto the upper well and incubated with vehicle (DPBS), CAD27 (10 and
20 µg/mL), or Csr27 (10 and 20 µg/mL), respectively, in a humidified 5% CO2 incubator at 37 ◦C for
6 h. The cells on the upper side of the filter were removed. Those that had migrated to the lower side
were fixed in absolute methanol, stained with 10% Giemsa solution (Merck, Darmstadt, Germany) and
five high power fields from each well were counted under a bright field phase contrast microscope
(Olympus BX40; Olympus Optical Co., Tokyo, Japan).
4.7. Aortic Ring Assay
This ex vivo aortic ring angiogenesis assay was performed as described previously [26]. Briefly,
the thoracic aortas were excised from 3 week-old male Sprague Dawley rats and immediately placed
into prechilled DMEM containing 10% FBS. Clotted blood inside the aorta was flushed with media,
and the peri-adventitial fibroadipose tissue was removed. Aortas were then cut into cross-sectional
rings approximately 1–1.5 mm in length. Rings were placed into a 24-well plate containing 0.5 mL
of cold BD Matrigel™ Basement Membrane Matrix supplemented with MCDB131 medium (catalog
no. 10372019, Invitrogen) and incubated at 37 ◦C until the Matrigel polymerized. Subsequently, aortic
rings were treated with vehicle (DPBS), CAD27 (10 µg/mL), or Csr27 (10 µg/mL) and maintained
in a humidified 5% CO2 incubator at 37 ◦C for five days. Microvascular sprouting from each aortic
ring were examined and imaged daily under a bright field phase contrast microscope (Olympus BX40,
Shinjuku, Tokyo, Japan). The greatest distances from the aortic ring body to the end of the vascular
sprouts (sprout length) were measured by Image J version 1.48 software at three distinct points per
ring and in three different rings per treatment group.
4.8. Animal and Ethical Approval
All animals were handled in accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research for the experiments performed in this study, and was obtained
from the Institutional Animal Care and Use Committee (IACUC) of Kaohsiung Veterans General
Hospital (vghks-103-A010, 26 July 2013). The pigmented Brown Norway rats (eight week-old,
female) and Sprague Dawley rats (three week-old, male) were purchased from National Animal
Center, Taipei, Taiwan. Rats were housed in standard cages, with free access to food and water in
a temperature-controlled environment under a 12-h light (50 lux illumination) and 12-h dark (<10 lux
illumination) cycle to minimize possible light-induced damage to the eye.
Int. J. Mol. Sci. 2018, 19, 2993 11 of 14
4.9. Generation of CNV by Laser Photocoagulation
The CNV lesions were induced in rat eyes by laser photocoagulation as previously described [26].
Briefly, Brown Norway rats were anesthetized with an intramuscular injection of a mixture of 2%
xylocaine (0.15 mL/kg body weight, Astra, Astra Sodertalje, Sweden) and ketamine (50 mg/kg
body weight, Parke-Davis, Morris Plains, NJ, USA). Pupils were dilated with 1% tropicamide (Alcon
Laboratories, Fort Worth, TX, USA). A piece of cover glass served as the contact lens to improve the
visibility of the fundus. Argon laser (Novus Omni; Coherent, Palo Alto, CA, USA) irradiation was
delivered through a slit lamp (Carl Zeiss, Oberkochen, Germany). Laser parameters: spot size of 50 µm,
power of 400 mW, and exposure duration of 0.05 s. Disruption of Bruch’s membrane was detected by
the emergence of a bubble at the center of photocoagulation in the laser spotted zone. Six lesions were
generated in each eye at the 1, 3, 5, 7, 9, and 11 o’clock positions located at equidistance from the optic
disk and between the major retinal vessels.
4.10. Intravitreal Injection and Topical Application
One day after laser-induced CNV induction, rats were anesthetized with a combination of
xylocaine (0.15 mL/kg body weight) and ketamine (50 mg/kg body weight). Intravitreal injection
was performed under a surgical microscope as previously described [18]. After a small puncture
through the conjunctiva and sclera was created using a 30 gauge needle, a 32 gauge blunt needle
connected to a 10-µL Hamilton syringe was inserted into the vitreous and 5 µL of DPBS suspension
containing Lucentis® (ranibizumab, 50 µg; Novartis, Basel, Switzerland), CAD27 (10 and 20 µg),
or vehicle (DPBS) was injected into one eye of each rat using a UMP3–2 Ultra Micro Pump (World
Precision Instruments, Sarasota, FL, USA) at a rate of 100 nL/s. Only a single injection was permitted
in the CNV rat. The CAD27 (10 and 20 µg/mL) were formulated as eye drop in DPBS and topical
installed three times a day in the rat eye after CNV induction for 28 days.
4.11. Electroretinogram (ERG)
The single bright flash ERGs (UTAS-E 300; LKC Technology, Gaithersburg, MD, USA) under
a dark-adapted environment (~12 h) were performed to assess the effect of intravitreal or topical
administration of CAD27 on retinal function. After at least 30 min of darkness adaptation, rats
were anesthetized. Gold foil was placed on the cornea with 2% methylcellulose gel (Omni Vision,
Neuhausen, Switzerland). A reference electrode was attached to the shaven skin of the head and
a ground electrode clipped to the rat’s ear. After reducing the background noise below 60 Hz, a single
flash of bright light (duration, 100 ms), 30 cm from the eye, was used as the light stimulus. Responses
were amplified with a gain setting ±500 µV and filtered with low 0.3 Hz and high 500 Hz from
an amplifier. Data were acquired, digitized, and analyzed using EM for Windows, version 2.6.
4.12. Fundus Fluorescein Angiography (FFA)
The size of CNV lesions were evaluated by FFA analysis using a digital fundus camera (Visupac
450, Ziess FF450, Oberkochen, Germany) on day 24 after laser photocoagulation. The rats were
anaesthetized and the fluorescein sodium solution (10% Fluorescite; Alcon, Fort Worth, TX, USA)
was intraperitoneally injected at a dose of 0.1 mL/kg body weight. Late-phase angiograms were
obtained at 8 min after injection, and digital fundus pictures of bilateral eyes were taken within
1 min. The incidence of choroidal neovascularization was defined when early hyperfluorescence
with the onset of late leakage was present at the site of laser injury [26]. The extent of the leakage
of the CNV lesions were graded using a leakage score system. Score 0 indicates no staining (no
hyperfluorescence), Score 1 indicates staining (hyperfluorescence without leakage), Score 2 indicates
moderate leakage (hyperfluorescence in the early or midtransit images and late leakage), and Score
3 indicates heavy leakage (bright hyperfluorescence in the transit images and late leakage beyond
treated areas). The scores were assessed by two independent ophthalmologists who were masked to
the experimental design.
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4.13. Quantification of Choroidal Vascularity by Flat-Mounted Analysis
Rats were euthanized 28 days after laser photocoagulation. The choroidal blood vessels in rat
eyes were labeled by perfusion with fluorescein isothiocyanate (FITC)-dextran (2 × 106 MW; catalog
no. FD2000S, Sigma-Aldrich, St. Louis, MO, USA) [28,29]. Briefly, the rats were anaesthetized and
subjected to an intracardiac perfusion of approximately 50 mL of lactated Ringer solution, followed by
20 mL of FITC-dextran in lactated Ringer solution (5 mg/mL) with gelatin (10%, w/v; catalog no. G9382,
Sigma-Aldrich, Saint Louis, MO, USA). The eyes were enucleated and fixed in 10% phosphate-buffered
formalin for 2 h at room temperature. After the cornea and lens were removed, the retinal pigment
epithelium (RPE)/choroid/sclera flat-mounts were obtained on microscopic slides. Flat-mounts were
imaged with a laser-scanning confocal fluorescence microscope. The areas of hyperfluorescence
associated with each CNV lesion was measured by observers who were blinded to the groups using
ImageJ version 1.48 software.
4.14. Statistical Analysis
Results are presented as means ± standard errors of the means (SEM). The experimental data
was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons test or two-tailed
Student’s t-test (GraphPad Prism software version 7.0). A value of p less than 0.05 was considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
2993/s1.
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